SGLT2i, Pioglitazone, and Ketone Production in T2D

NCT07053319 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Empagliflozin 25 MG plus Pioglitazone placebo
DRUG: Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo
DRUG: Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d)
DRUG: Pioglitazone placebo + Empagliflozin placebo

Sponsor

The University of Texas Health Science Center at San Antonio

Collaborators

[object Object]